Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 876

1.

Income level and inequality as complement to geographical differences in cardiovascular trials.

Ferreira JP, Rossignol P, Dewan P, Lamiral Z, White WB, Pitt B, McMurray JJV, Zannad F.

Am Heart J. 2019 Sep 1;218:66-74. doi: 10.1016/j.ahj.2019.08.019. [Epub ahead of print]

PMID:
31707330
2.

Lung ultrasound: monitoring congestion in patients with heart failure.

Platz E, Solomon SD, McMurray JJV.

Eur J Heart Fail. 2019 Nov 8. doi: 10.1002/ejhf.1636. [Epub ahead of print] No abstract available.

PMID:
31702095
3.

Effects of apixaban compared with warfarin as gain in event-free time - a novel assessment of the results of the ARISTOTLE trial.

Berglund E, Wallentin L, Oldgren J, Renlund H, Alexander JH, Granger CB, Hohnloser SH, Hylek EM, Lopes RD, McMurray JJ, Lytsy P.

Eur J Prev Cardiol. 2019 Nov 7:2047487319886959. doi: 10.1177/2047487319886959. [Epub ahead of print]

PMID:
31698965
4.

Visit-to-visit blood pressure variation and outcomes in heart failure with reduced ejection fraction: findings from the Eplerenone in Patients with Systolic Heart Failure and Mild Symptoms trial.

Monzo L, Ferreira JP, Abreu P, Szumski A, Böhm M, McMurray JJV, Pitt B, Swedberg K, van Veldhuisen DJ, Girerd N, Vincent J, Zannad F, Rossignol P.

J Hypertens. 2019 Oct 3. doi: 10.1097/HJH.0000000000002275. [Epub ahead of print]

PMID:
31584516
5.

Lung Ultrasound in Acute Heart Failure: Prevalence of Pulmonary Congestion and Short- and Long-Term Outcomes.

Platz E, Campbell RT, Claggett B, Lewis EF, Groarke JD, Docherty KF, Lee MMY, Merz AA, Silverman M, Swamy V, Lindner M, Rivero J, Solomon SD, McMurray JJV.

JACC Heart Fail. 2019 Oct;7(10):849-858. doi: 10.1016/j.jchf.2019.07.008.

PMID:
31582107
6.

Optimizing heart failure treatment following cardiac resynchronization therapy.

Jorsal A, Pryds K, McMurray JJV, Wiggers H, Sommer A, Nielsen JC, Nielsen RR.

Clin Res Cardiol. 2019 Sep 26. doi: 10.1007/s00392-019-01553-4. [Epub ahead of print]

PMID:
31559483
7.

Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction.

McMurray JJV, Solomon SD, Inzucchi SE, Køber L, Kosiborod MN, Martinez FA, Ponikowski P, Sabatine MS, Anand IS, Bělohlávek J, Böhm M, Chiang CE, Chopra VK, de Boer RA, Desai AS, Diez M, Drozdz J, Dukát A, Ge J, Howlett JG, Katova T, Kitakaze M, Ljungman CEA, Merkely B, Nicolau JC, O'Meara E, Petrie MC, Vinh PN, Schou M, Tereshchenko S, Verma S, Held C, DeMets DL, Docherty KF, Jhund PS, Bengtsson O, Sjöstrand M, Langkilde AM; DAPA-HF Trial Committees and Investigators.

N Engl J Med. 2019 Sep 19. doi: 10.1056/NEJMoa1911303. [Epub ahead of print]

PMID:
31535829
8.

Prognostic Implications of Congestion on Physical Examination Among Contemporary Patients With Heart Failure and Reduced Ejection Fraction: PARADIGM-HF.

Selvaraj S, Claggett B, Pozzi A, McMurray JJV, Jhund PS, Packer M, Desai AS, Lewis EF, Vaduganathan M, Lefkowitz MP, Rouleau JL, Shi VC, Zile MR, Swedberg K, Solomon SD.

Circulation. 2019 Oct 22;140(17):1369-1379. doi: 10.1161/CIRCULATIONAHA.119.039920. Epub 2019 Sep 12.

PMID:
31510768
9.

PIONEER-HF: a new frontier in the role of neprilysin inhibition in the management of heart failure with reduced ejection fraction.

Docherty KF, McMurray JJV.

Cardiovasc Res. 2019 Nov 1;115(13):e136-e139. doi: 10.1093/cvr/cvz223. No abstract available.

PMID:
31497841
10.

Temporal Trends and Patterns in Mortality After Incident Heart Failure: A Longitudinal Analysis of 86 000 Individuals.

Conrad N, Judge A, Canoy D, Tran J, Pinho-Gomes AC, Millett ERC, Salimi-Khorshidi G, Cleland JG, McMurray JJV, Rahimi K.

JAMA Cardiol. 2019 Sep 3. doi: 10.1001/jamacardio.2019.3593. [Epub ahead of print]

11.

Association of diabetes and kidney function according to age and systolic function with the incidence of sudden cardiac death and non-sudden cardiac death in myocardial infarction survivors with heart failure.

Coiro S, Girerd N, Sharma A, Rossignol P, Tritto I, Pitt B, Pfeffer MA, McMurray JJV, Ambrosio G, Dickstein K, Moss A, Zannad F.

Eur J Heart Fail. 2019 Oct;21(10):1248-1258. doi: 10.1002/ejhf.1541. Epub 2019 Sep 2.

PMID:
31476097
12.

Angiotensin-Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction.

Solomon SD, McMurray JJV, Anand IS, Ge J, Lam CSP, Maggioni AP, Martinez F, Packer M, Pfeffer MA, Pieske B, Redfield MM, Rouleau JL, van Veldhuisen DJ, Zannad F, Zile MR, Desai AS, Claggett B, Jhund PS, Boytsov SA, Comin-Colet J, Cleland J, Düngen HD, Goncalvesova E, Katova T, Kerr Saraiva JF, Lelonek M, Merkely B, Senni M, Shah SJ, Zhou J, Rizkala AR, Gong J, Shi VC, Lefkowitz MP; PARAGON-HF Investigators and Committees.

N Engl J Med. 2019 Oct 24;381(17):1609-1620. doi: 10.1056/NEJMoa1908655. Epub 2019 Sep 1.

PMID:
31475794
13.

World Heart Federation Roadmap for Heart Failure.

Ferreira JP, Kraus S, Mitchell S, Perel P, Piñeiro D, Chioncel O, Colque R, de Boer RA, Gomez-Mesa JE, Grancelli H, Lam CSP, Martinez-Rubio A, McMurray JJV, Mebazaa A, Panjrath G, Piña IL, Sani M, Sim D, Walsh M, Yancy C, Zannad F, Sliwa K.

Glob Heart. 2019 Sep;14(3):197-214. doi: 10.1016/j.gheart.2019.07.004. No abstract available.

PMID:
31451235
14.

Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials.

Kristensen SL, Rørth R, Jhund PS, Docherty KF, Sattar N, Preiss D, Køber L, Petrie MC, McMurray JJV.

Lancet Diabetes Endocrinol. 2019 Oct;7(10):776-785. doi: 10.1016/S2213-8587(19)30249-9. Epub 2019 Aug 14.

PMID:
31422062
15.

Phosphodiesterase-9 Inhibition in Heart Failure: A Further Opportunity to Augment the Effects of Natriuretic Peptides?

McMurray JJV, Docherty KF.

J Am Coll Cardiol. 2019 Aug 20;74(7):902-904. doi: 10.1016/j.jacc.2019.07.008. No abstract available.

PMID:
31416534
16.

From ACE Inhibitors/ARBs to ARNIs in Coronary Artery Disease and Heart Failure (Part 2/5).

Leong DP, McMurray JJV, Joseph PG, Yusuf S.

J Am Coll Cardiol. 2019 Aug 6;74(5):683-698. doi: 10.1016/j.jacc.2019.04.068. Review.

PMID:
31370961
17.

Age-Related Characteristics and Outcomes of Patients With Heart Failure With Preserved Ejection Fraction.

Tromp J, Shen L, Jhund PS, Anand IS, Carson PE, Desai AS, Granger CB, Komajda M, McKelvie RS, Pfeffer MA, Solomon SD, Køber L, Swedberg K, Zile MR, Pitt B, Lam CSP, McMurray JJV.

J Am Coll Cardiol. 2019 Aug 6;74(5):601-612. doi: 10.1016/j.jacc.2019.05.052.

PMID:
31370950
18.

Statins in the Prevention and Treatment of Heart Failure: a Review of the Evidence.

Lee MMY, Sattar N, McMurray JJV, Packard CJ.

Curr Atheroscler Rep. 2019 Jul 27;21(10):41. doi: 10.1007/s11883-019-0800-z. Review.

19.

The Dapagliflozin And Prevention of Adverse-outcomes in Heart Failure (DAPA-HF) trial: baseline characteristics.

McMurray JJV, DeMets DL, Inzucchi SE, Køber L, Kosiborod MN, Langkilde AM, Martinez FA, Bengtsson O, Ponikowski P, Sabatine MS, Sjöstrand M, Solomon SD; DAPA-HF Committees and Investigators.

Eur J Heart Fail. 2019 Jul 15. doi: 10.1002/ejhf.1548. [Epub ahead of print]

PMID:
31309699
20.

Health-Related Quality of Life in Heart Failure With Preserved Ejection Fraction: The PARAGON-HF Trial.

Chandra A, Vaduganathan M, Lewis EF, Claggett BL, Rizkala AR, Wang W, Lefkowitz MP, Shi VC, Anand IS, Ge J, Lam CSP, Maggioni AP, Martinez F, Packer M, Pfeffer MA, Pieske B, Redfield MM, Rouleau JL, Van Veldhuisen DJ, Zannad F, Zile MR, McMurray JJV, Solomon SD; PARAGON-HF Investigators.

JACC Heart Fail. 2019 Oct;7(10):862-874. doi: 10.1016/j.jchf.2019.05.015. Epub 2019 Jul 10.

PMID:
31302043
21.

Microvascular Disease in Patients With Diabetes With Heart Failure and Reduced Ejection Versus Preserved Ejection Fraction.

Tromp J, Lim SL, Tay WT, Teng TK, Chandramouli C, Ouwerkerk W, Wander GS, Sawhney JPS, Yap J, MacDonald MR, Ling LH, Sattar N, McMurray JJV, Richards AM, Anand I, Lam CSP; ASIAN-HF Investigators.

Diabetes Care. 2019 Sep;42(9):1792-1799. doi: 10.2337/dc18-2515. Epub 2019 Jul 10.

PMID:
31292141
22.

Insulin treatment and clinical outcomes in patients with diabetes and heart failure with preserved ejection fraction.

Shen L, Rørth R, Cosmi D, Kristensen SL, Petrie MC, Cosmi F, Latini R, Køber L, Anand IS, Carson PE, Granger CB, Komajda M, McKelvie RS, Solomon SD, Staszewsky L, Swedberg K, Huynh T, Zile MR, Jhund PS, McMurray JJV.

Eur J Heart Fail. 2019 Aug;21(8):974-984. doi: 10.1002/ejhf.1535. Epub 2019 Jul 4.

PMID:
31271255
23.

Expert consensus document: Reporting checklist for quantification of pulmonary congestion by lung ultrasound in heart failure.

Platz E, Jhund PS, Girerd N, Pivetta E, McMurray JJV, Peacock WF, Masip J, Martin-Sanchez FJ, Miró Ò, Price S, Cullen L, Maisel AS, Vrints C, Cowie MR, DiSomma S, Bueno H, Mebazaa A, Gualandro DM, Tavares M, Metra M, Coats AJS, Ruschitzka F, Seferovic PM, Mueller C; Study Group on Acute Heart Failure of the Acute Cardiovascular Care Association and the Heart Failure Association of the European Society of Cardiology.

Eur J Heart Fail. 2019 Jul;21(7):844-851. doi: 10.1002/ejhf.1499. Epub 2019 Jun 19.

PMID:
31218825
24.

Winter Peaks in Heart Failure: An Inevitable or Preventable Consequence of Seasonal Vulnerability?

Stewart S, Moholdt TT, Burrell LM, Sliwa K, Mocumbi AO, McMurray JJ, Keates AK, Hawley JA.

Card Fail Rev. 2019 May 24;5(2):83-85. doi: 10.15420/cfr.2018.40.2. eCollection 2019 May. Review.

25.

Sacubitril/Valsartan in Asian Patients with Heart Failure with Reduced Ejection Fraction.

Dewan P, Docherty KF, McMurray JJV.

Korean Circ J. 2019 Jun;49(6):469-484. doi: 10.4070/kcj.2019.0136. Review.

26.

Rationale and design for the development of a novel nitroxyl donor in patients with acute heart failure.

Felker GM, Borentain M, Cleland JG, DeSouza MM, Kessler PD, O'Connor CM, Seiffert D, Teerlink JR, Voors AA, McMurray JJV.

Eur J Heart Fail. 2019 Aug;21(8):1022-1031. doi: 10.1002/ejhf.1504. Epub 2019 Jun 6.

PMID:
31168885
27.

Effect of Neladenoson Bialanate on Exercise Capacity Among Patients With Heart Failure With Preserved Ejection Fraction: A Randomized Clinical Trial.

Shah SJ, Voors AA, McMurray JJV, Kitzman DW, Viethen T, Bomfim Wirtz A, Huang E, Pap AF, Solomon SD.

JAMA. 2019 Jun 4;321(21):2101-2112. doi: 10.1001/jama.2019.6717.

PMID:
31162568
28.

Diagnostic tests, drug prescriptions, and follow-up patterns after incident heart failure: A cohort study of 93,000 UK patients.

Conrad N, Judge A, Canoy D, Tran J, O'Donnell J, Nazarzadeh M, Salimi-Khorshidi G, Hobbs FDR, Cleland JG, McMurray JJV, Rahimi K.

PLoS Med. 2019 May 21;16(5):e1002805. doi: 10.1371/journal.pmed.1002805. eCollection 2019 May.

29.

Outcomes and Effect of Treatment According to Etiology in HFrEF: An Analysis of PARADIGM-HF.

Balmforth C, Simpson J, Shen L, Jhund PS, Lefkowitz M, Rizkala AR, Rouleau JL, Shi V, Solomon SD, Swedberg K, Zile MR, Packer M, McMurray JJV.

JACC Heart Fail. 2019 Jun;7(6):457-465. doi: 10.1016/j.jchf.2019.02.015. Epub 2019 May 8.

30.

Estimated Long-Term Survival With Eplerenone.

Stienen S, Ferreira JP, Vincent J, Busselen M, Li B, McMurray JJV, Pitt B, Girerd N, Rossignol P, Zannad F.

J Am Coll Cardiol. 2019 May 14;73(18):2357-2359. doi: 10.1016/j.jacc.2019.02.043. No abstract available.

PMID:
31072582
31.

Urinalysis: A Window to the Heart.

McMurray JJV.

JACC Heart Fail. 2019 May;7(5):402-403. doi: 10.1016/j.jchf.2019.04.002. No abstract available.

PMID:
31047020
32.

Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial.

Heerspink HJL, Parving HH, Andress DL, Bakris G, Correa-Rotter R, Hou FF, Kitzman DW, Kohan D, Makino H, McMurray JJV, Melnick JZ, Miller MG, Pergola PE, Perkovic V, Tobe S, Yi T, Wigderson M, de Zeeuw D; SONAR Committees and Investigators.

Lancet. 2019 May 11;393(10184):1937-1947. doi: 10.1016/S0140-6736(19)30772-X. Epub 2019 Apr 14. Erratum in: Lancet. 2019 May 11;393(10184):1936.

PMID:
30995972
33.

Prior Pacemaker Implantation and Clinical Outcomes in Patients With Heart Failure and Preserved Ejection Fraction.

Shen L, Jhund PS, Docherty KF, Petrie MC, Anand IS, Carson PE, Desai AS, Granger CB, Komajda M, McKelvie RS, Pfeffer MA, Solomon SD, Swedberg K, Zile MR, McMurray JJV.

JACC Heart Fail. 2019 May;7(5):418-427. doi: 10.1016/j.jchf.2018.12.006. Epub 2019 Apr 10.

PMID:
30981744
34.

Personalized medicine and hospitalization for heart failure: if we understand it, we may be successful in treating it.

Ahmad FA, Petrie MC, McMurray JJV, Lang NN.

Eur J Heart Fail. 2019 Jun;21(6):699-702. doi: 10.1002/ejhf.1463. Epub 2019 Apr 11. No abstract available.

35.

Anticoagulation therapy in heart failure and sinus rhythm: a systematic review and meta-analysis.

Beggs SAS, Rørth R, Gardner RS, McMurray JJV.

Heart. 2019 Sep;105(17):1325-1334. doi: 10.1136/heartjnl-2018-314381. Epub 2019 Apr 8.

PMID:
30962190
36.

Prognostic Implications of Changes in Amino-Terminal Pro-B-Type Natriuretic Peptide in Acute Decompensated Heart Failure: Insights From ASCEND-HF.

Grodin JL, Liebo MJ, Butler J, Metra M, Felker GM, Hernandez AF, Voors AA, McMurray JJ, Armstrong PW, O'Connor C, Starling RC, Troughton RW, Tang WHW.

J Card Fail. 2019 Sep;25(9):703-711. doi: 10.1016/j.cardfail.2019.04.002. Epub 2019 Apr 4.

PMID:
30953792
37.

Mean BMI, visit-to-visit BMI variability and BMI changes during follow-up in patients with acute myocardial infarction with systolic dysfunction and/or heart failure: insights from the High-Risk Myocardial Infarction Initiative.

Stienen S, Ferreira JP, Girerd N, Duarte K, Lamiral Z, McMurray JJV, Pitt B, Dickstein K, Zannad F, Rossignol P; High-Risk Myocardial Infarction Database Initiative.

Clin Res Cardiol. 2019 Nov;108(11):1215-1225. doi: 10.1007/s00392-019-01453-7. Epub 2019 Apr 5.

PMID:
30953180
38.

"Real World" Eligibility for Sacubitril/Valsartan in Unselected Heart Failure Patients: Data from the Swedish Heart Failure Registry.

Simpson J, Benson L, Jhund PS, Dahlström U, McMurray JJV, Lund LH.

Cardiovasc Drugs Ther. 2019 Jun;33(3):315-322. doi: 10.1007/s10557-019-06873-1.

39.

A trial to evaluate the effect of the sodium-glucose co-transporter 2 inhibitor dapagliflozin on morbidity and mortality in patients with heart failure and reduced left ventricular ejection fraction (DAPA-HF).

McMurray JJV, DeMets DL, Inzucchi SE, Køber L, Kosiborod MN, Langkilde AM, Martinez FA, Bengtsson O, Ponikowski P, Sabatine MS, Sjöstrand M, Solomon SD; DAPA-HF Committees and Investigators.

Eur J Heart Fail. 2019 May;21(5):665-675. doi: 10.1002/ejhf.1432. Epub 2019 Mar 21.

40.

The Serendipitous Story of SGLT2 Inhibitors in Heart Failure.

Verma S, McMurray JJV.

Circulation. 2019 May 28;139(22):2537-2541. doi: 10.1161/CIRCULATIONAHA.119.040514. Epub 2019 Mar 18. No abstract available.

PMID:
30882236
41.

N-Terminal Pro-B-Type Natriuretic Peptide Levels for Risk Prediction in Patients With Heart Failure and Preserved Ejection Fraction According to Atrial Fibrillation Status.

Kristensen SL, Mogensen UM, Jhund PS, Rørth R, Anand IS, Carson PE, Desai AS, Pitt B, Pfeffer MA, Solomon SD, Zile MR, Køber L, McMurray JJV.

Circ Heart Fail. 2019 Mar;12(3):e005766. doi: 10.1161/CIRCHEARTFAILURE.118.005766.

PMID:
30871349
42.

B-Type Natriuretic Peptide During Treatment With Sacubitril/Valsartan: The PARADIGM-HF Trial.

Myhre PL, Vaduganathan M, Claggett B, Packer M, Desai AS, Rouleau JL, Zile MR, Swedberg K, Lefkowitz M, Shi V, McMurray JJV, Solomon SD.

J Am Coll Cardiol. 2019 Mar 26;73(11):1264-1272. doi: 10.1016/j.jacc.2019.01.018. Epub 2019 Mar 4.

PMID:
30846338
43.

Effects of Sacubitril/Valsartan on Biomarkers of Extracellular Matrix Regulation in Patients With HFrEF.

Zile MR, O'Meara E, Claggett B, Prescott MF, Solomon SD, Swedberg K, Packer M, McMurray JJV, Shi V, Lefkowitz M, Rouleau J.

J Am Coll Cardiol. 2019 Feb 26;73(7):795-806. doi: 10.1016/j.jacc.2018.11.042.

PMID:
30784673
44.

Renal function stratified dose comparisons of eplerenone versus placebo in the EMPHASIS-HF trial.

Ferreira JP, Abreu P, McMurray JJV, van Veldhuisen DJ, Swedberg K, Pocock SJ, Vincent J, Lins K, Rossignol P, Pitt B, Zannad F.

Eur J Heart Fail. 2019 Mar;21(3):345-351. doi: 10.1002/ejhf.1400. Epub 2019 Feb 15.

PMID:
30768732
45.

Reduced loop diuretic use in patients taking sacubitril/valsartan compared with enalapril: the PARADIGM-HF trial.

Vardeny O, Claggett B, Kachadourian J, Desai AS, Packer M, Rouleau J, Zile MR, Swedberg K, Lefkowitz M, Shi V, McMurray JJV, Solomon SD.

Eur J Heart Fail. 2019 Mar;21(3):337-341. doi: 10.1002/ejhf.1402. Epub 2019 Feb 11.

46.

Income Inequality and Outcomes in Heart Failure: A Global Between-Country Analysis.

Dewan P, Rørth R, Jhund PS, Ferreira JP, Zannad F, Shen L, Køber L, Abraham WT, Desai AS, Dickstein K, Packer M, Rouleau JL, Solomon SD, Swedberg K, Zile MR, McMurray JJV; PARADIGM-HF and ATMOSPHERE Investigators.

JACC Heart Fail. 2019 Apr;7(4):336-346. doi: 10.1016/j.jchf.2018.11.005. Epub 2019 Feb 6.

47.

Efficacy of an implantable cardioverter-defibrillator in patients with diabetes and heart failure and reduced ejection fraction.

Rørth R, Dewan P, Kristensen SL, Jhund PS, Petrie MC, Køber L, McMurray JJV.

Clin Res Cardiol. 2019 Aug;108(8):868-877. doi: 10.1007/s00392-019-01415-z. Epub 2019 Jan 28.

48.

Metformin use and cardiovascular events in patients with type 2 diabetes and chronic kidney disease.

Charytan DM, Solomon SD, Ivanovich P, Remuzzi G, Cooper ME, McGill JB, Parving HH, Parfrey P, Singh AK, Burdmann EA, Levey AS, Eckardt KU, McMurray JJV, Weinrauch LA, Liu J, Claggett B, Lewis EF, Pfeffer MA.

Diabetes Obes Metab. 2019 May;21(5):1199-1208. doi: 10.1111/dom.13642. Epub 2019 Mar 4.

PMID:
30672083
49.

Retinopathy, Neuropathy, and Subsequent Cardiovascular Events in Patients with Type 2 Diabetes and Acute Coronary Syndrome in the ELIXA: The Importance of Disease Duration.

Seferovic JP, Bentley-Lewis R, Claggett B, Diaz R, Gerstein HC, Køber LV, Lawson FC, Lewis EF, Maggioni AP, McMurray JJV, Probstfield JL, Riddle MC, Solomon SD, Tardif JC, Pfeffer MA.

J Diabetes Res. 2018 Dec 16;2018:1631263. doi: 10.1155/2018/1631263. eCollection 2018.

50.

Response by Claggett et al to Letter Regarding Article, "Comparison of Time-to-First Event and Recurrent-Event Methods in Randomized Clinical Trials".

Claggett B, Pocock S, Wei LJ, Pfeffer MA, McMurray JJV, Solomon SD.

Circulation. 2019 Jan 15;139(3):422-423. doi: 10.1161/CIRCULATIONAHA.118.038478. No abstract available.

PMID:
30640547

Supplemental Content

Loading ...
Support Center